BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xcovery Announces Presentation of Clinical Data at Upcoming American Society of Clinical Oncology Annual Meeting


5/18/2012 9:16:41 AM

WEST PALM BEACH, FL--(Marketwire - May 18, 2012) - Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.

The data will be presented in a poster presentation at the American Society of Clinical Oncology's (ASCO) Annual Meeting taking place on Friday, June 1 through Tuesday, June 5, 2012 in Chicago.

Poster PresentationTitle: A Phase I First-in-Human Trial of an Oral VEGFR Tyrosine Kinase Inhibitor (TKI), X-82, in Patients with Advanced Solid Tumors
Date & Time: Monday, June 4, 2012: 8:00 AM - 12:00 PM, CT
Abstract: #3041
Location: S Hall, A2

The poster will be made available for viewing on the company's website, www.xcovery.com, following the public presentation.

VEGFR tyrosine kinase inhibitors have demonstrated benefit in a variety of cancers. However, it has been well documented that the dosage and use of this class in combination with other therapies has been limited by side effects.

Xcovery's lead clinical candidate, X-82, is a novel, potent, oral dual VEGFR/PDGFR inhibitor, designed to minimize side effects. The preliminary Phase 1 data described in this poster presentation suggests that X-82 has unique pharmacokinetic and pharmacodynamic properties which differentiate it from competitive products in development and on the market.

About Xcovery
Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, PhD, Xcovery's vision is to successfully develop innovative oncology therapies to optimize patient outcomes. Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies that target a wide range of advanced tumors. X-82 was developed by Tyrogenex, an Xcovery company, funded by Biocatalyst International.


Media Contact:
Amanda Murphy or Donna LaVoie
LaVoie Group
Office: 978.745.4200 x107/ x103
amurphy@lavoiegroup.com
dlavoie@lavoiegroup.com

Business Development Contact:
Cheryl Calhoun
Vice President
(561) 835-9356
cheryl@xcovery.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES